Milan, Italy

Camilla Fowst

USPTO Granted Patents = 3 

Average Co-Inventor Count = 3.3

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2003-2008

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Camilla Fowst: Innovator in Antitumor Therapies

Introduction

Camilla Fowst is a notable inventor based in Milan, Italy. She has made significant contributions to the field of cancer treatment, holding a total of 3 patents. Her work focuses on innovative therapies that aim to improve patient outcomes in oncology.

Latest Patents

One of her latest patents is titled "Antitumor therapy comprising distamycin derivatives." This invention relates to an administration schedule that includes the intravenous administration of an α-halogen-acryloyl distamycin derivative, or a pharmaceutically acceptable salt thereof. This method allows for the treatment of various tumors in mammals. Another significant patent is "Method for predicting the sensitivity to chemotherapy." This invention provides a method for predicting a patient's sensitivity to chemotherapy by measuring glutathione (GSH) blood levels in patients undergoing chemotherapeutic treatment.

Career Highlights

Throughout her career, Camilla has worked with various organizations, including Nerviano Medical Sciences S.r.l. Her innovative approaches and research have positioned her as a key figure in the development of new cancer therapies.

Collaborations

Camilla has collaborated with notable professionals in her field, including Franzanne Vreeland and Maria Cristina Rosa Geroni. These collaborations have further enhanced her research and contributions to cancer treatment.

Conclusion

Camilla Fowst's work in antitumor therapies and her innovative patents demonstrate her commitment to advancing cancer treatment. Her contributions are vital in the ongoing fight against cancer, and her research continues to inspire future innovations in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…